Safety and Efficacy of T Cell Genetic Immunotherapy for HIV
NCT00131560
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
60
Enrollment
INDUSTRY
Sponsor class
Conditions
HIV Infection
Interventions
GENETIC:
VRX496-Modified Autologous T cells
Sponsor
VIRxSYS Corporation